
    
      Open label single intravenous dose, single group study. Eight subjects (ideally 4 male and 4
      female, minimum of two females) will be studied. The drug product will be a F901318 solution
      for infusion (6mg/mL). The dose will be 4 mg/kg delivered in the fasted state (8 hours
      minimum) by intravenous infusion over 2 hours. Each subject will be on study for
      approximately 6 weeks. Each subject will reside at the Clinical Research Unit (CRU) from Day
      -1 (the day before dosing) to Day 4 (72 hours post-dose). Blood samples for pharmacokinetic
      evaluation will be obtained up to and including 120 hours post dose. Safety and tolerability
      will also be assessed.

      Subjects will return to the clinical unit at 96 and 120 hours for pharmacokinetic blood
      sampling.

      All subjects will return for a post-study visit 8 to 10 days after the dose of study
      medication.
    
  